Serum levels of soluble E-selectin in women with breast cancer

S. M. Sheen-Chen, H. L. Eng, C. C. Huang, W. J. Chen

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Increasing evidence suggests that E-selectin contributes to tumour growth and metastasis, possibly by increasing angiogenesis and the adhesion of tumour cells to endothelial cells at distant sites. This study aimed to examine the relationship between preoperative levels of circulating soluble E-selectin and breast cancer. Methods: Sixty-four consecutive women undergoing surgery for invasive breast cancer were studied prospectively. Venous blood samples were collected before the operation. A control group consisted of 16 patients with a benign breast tumour (eight with fibrocystic disease and eight with fibroadenoma). Serum concentrations of soluble E-selectin were measured by the quantitative sandwich enzyme immunoassay technique and compared with clinicopathological information. Results: The mean(s.d.) serum level of soluble E-selectin in patients with invasive breast cancer was 73.7(20.9) ng/ml, compared with 36.3(5.6) ng/ml in the control group (P < 0.001). Furthermore, the serum levels of soluble E-selectin were significantly higher in women with oestrogen receptor-negative tumours (P = 0.001), poorly differentiated tumours (P < 0.001), more advanced primary tumour stage (P < 0.001), involved lymph nodes (P < 0.001), distant metastases (P < 0.001) and more advanced tumour node metastasis (TNM) stage (P < 0.001). On multivariate analysis, TNM stage (P < 0.001) was found to be an independent factor with regard to higher serum levels of soluble E-selectin. Conclusion: Preoperative serum levels of soluble E-selectin might reflect the severity of invasive breast cancer; further evaluation is warranted.

Original languageEnglish
Pages (from-to)1578-1581
Number of pages4
JournalBritish Journal of Surgery
Volume91
Issue number12
DOIs
Publication statusPublished - Dec 1 2004
Externally publishedYes

Fingerprint

E-Selectin
Breast Neoplasms
Serum
Neoplasms
Neoplasm Metastasis
Fibroadenoma
Control Groups
Immunoenzyme Techniques
Cell Adhesion
Estrogen Receptors
Multivariate Analysis
Endothelial Cells
Lymph Nodes
Growth

ASJC Scopus subject areas

  • Surgery

Cite this

Serum levels of soluble E-selectin in women with breast cancer. / Sheen-Chen, S. M.; Eng, H. L.; Huang, C. C.; Chen, W. J.

In: British Journal of Surgery, Vol. 91, No. 12, 01.12.2004, p. 1578-1581.

Research output: Contribution to journalArticle

Sheen-Chen, S. M. ; Eng, H. L. ; Huang, C. C. ; Chen, W. J. / Serum levels of soluble E-selectin in women with breast cancer. In: British Journal of Surgery. 2004 ; Vol. 91, No. 12. pp. 1578-1581.
@article{8936ea3391b84745872c163edd13909d,
title = "Serum levels of soluble E-selectin in women with breast cancer",
abstract = "Background: Increasing evidence suggests that E-selectin contributes to tumour growth and metastasis, possibly by increasing angiogenesis and the adhesion of tumour cells to endothelial cells at distant sites. This study aimed to examine the relationship between preoperative levels of circulating soluble E-selectin and breast cancer. Methods: Sixty-four consecutive women undergoing surgery for invasive breast cancer were studied prospectively. Venous blood samples were collected before the operation. A control group consisted of 16 patients with a benign breast tumour (eight with fibrocystic disease and eight with fibroadenoma). Serum concentrations of soluble E-selectin were measured by the quantitative sandwich enzyme immunoassay technique and compared with clinicopathological information. Results: The mean(s.d.) serum level of soluble E-selectin in patients with invasive breast cancer was 73.7(20.9) ng/ml, compared with 36.3(5.6) ng/ml in the control group (P < 0.001). Furthermore, the serum levels of soluble E-selectin were significantly higher in women with oestrogen receptor-negative tumours (P = 0.001), poorly differentiated tumours (P < 0.001), more advanced primary tumour stage (P < 0.001), involved lymph nodes (P < 0.001), distant metastases (P < 0.001) and more advanced tumour node metastasis (TNM) stage (P < 0.001). On multivariate analysis, TNM stage (P < 0.001) was found to be an independent factor with regard to higher serum levels of soluble E-selectin. Conclusion: Preoperative serum levels of soluble E-selectin might reflect the severity of invasive breast cancer; further evaluation is warranted.",
author = "Sheen-Chen, {S. M.} and Eng, {H. L.} and Huang, {C. C.} and Chen, {W. J.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1002/bjs.4513",
language = "English",
volume = "91",
pages = "1578--1581",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Serum levels of soluble E-selectin in women with breast cancer

AU - Sheen-Chen, S. M.

AU - Eng, H. L.

AU - Huang, C. C.

AU - Chen, W. J.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background: Increasing evidence suggests that E-selectin contributes to tumour growth and metastasis, possibly by increasing angiogenesis and the adhesion of tumour cells to endothelial cells at distant sites. This study aimed to examine the relationship between preoperative levels of circulating soluble E-selectin and breast cancer. Methods: Sixty-four consecutive women undergoing surgery for invasive breast cancer were studied prospectively. Venous blood samples were collected before the operation. A control group consisted of 16 patients with a benign breast tumour (eight with fibrocystic disease and eight with fibroadenoma). Serum concentrations of soluble E-selectin were measured by the quantitative sandwich enzyme immunoassay technique and compared with clinicopathological information. Results: The mean(s.d.) serum level of soluble E-selectin in patients with invasive breast cancer was 73.7(20.9) ng/ml, compared with 36.3(5.6) ng/ml in the control group (P < 0.001). Furthermore, the serum levels of soluble E-selectin were significantly higher in women with oestrogen receptor-negative tumours (P = 0.001), poorly differentiated tumours (P < 0.001), more advanced primary tumour stage (P < 0.001), involved lymph nodes (P < 0.001), distant metastases (P < 0.001) and more advanced tumour node metastasis (TNM) stage (P < 0.001). On multivariate analysis, TNM stage (P < 0.001) was found to be an independent factor with regard to higher serum levels of soluble E-selectin. Conclusion: Preoperative serum levels of soluble E-selectin might reflect the severity of invasive breast cancer; further evaluation is warranted.

AB - Background: Increasing evidence suggests that E-selectin contributes to tumour growth and metastasis, possibly by increasing angiogenesis and the adhesion of tumour cells to endothelial cells at distant sites. This study aimed to examine the relationship between preoperative levels of circulating soluble E-selectin and breast cancer. Methods: Sixty-four consecutive women undergoing surgery for invasive breast cancer were studied prospectively. Venous blood samples were collected before the operation. A control group consisted of 16 patients with a benign breast tumour (eight with fibrocystic disease and eight with fibroadenoma). Serum concentrations of soluble E-selectin were measured by the quantitative sandwich enzyme immunoassay technique and compared with clinicopathological information. Results: The mean(s.d.) serum level of soluble E-selectin in patients with invasive breast cancer was 73.7(20.9) ng/ml, compared with 36.3(5.6) ng/ml in the control group (P < 0.001). Furthermore, the serum levels of soluble E-selectin were significantly higher in women with oestrogen receptor-negative tumours (P = 0.001), poorly differentiated tumours (P < 0.001), more advanced primary tumour stage (P < 0.001), involved lymph nodes (P < 0.001), distant metastases (P < 0.001) and more advanced tumour node metastasis (TNM) stage (P < 0.001). On multivariate analysis, TNM stage (P < 0.001) was found to be an independent factor with regard to higher serum levels of soluble E-selectin. Conclusion: Preoperative serum levels of soluble E-selectin might reflect the severity of invasive breast cancer; further evaluation is warranted.

UR - http://www.scopus.com/inward/record.url?scp=10244241827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244241827&partnerID=8YFLogxK

U2 - 10.1002/bjs.4513

DO - 10.1002/bjs.4513

M3 - Article

C2 - 15386328

AN - SCOPUS:10244241827

VL - 91

SP - 1578

EP - 1581

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 12

ER -